Pionyr Immunotherapeutics, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals

Other Names/Subsidiaries

  • Gilead Sciences, Inc.
See more in Biomedtracker

Latest on Pionyr Immunotherapeutics, Inc.

Scrip

Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS

 
• By Joseph Haas and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

Scrip

Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Leo To Pay $14m For Timber, Plus Milest

Scrip

Gilead Licenses Novel Immunotherapy From Jounce

 
• By Joseph Haas

Who: Gilead Sciences/Jounce Therapeutics What: In its sixth major cancer deal of 2020, Gilead will license a preclinical immuno-oncology agent from Jounce that is thought to offer potential in both